ArticleJournal of clinical microbiology2002
Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes of Japanese and European patients with sarcoidosis.
Article in Journal of clinical microbiology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 133 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
133 citing papers in PubMed, 3 syntheses or guidelines pooled it, 439 citations in OpenAlex.
- Is there any association between Sarcoidosis and infectious agents?: a systematic review and meta-analysis.BMC pulmonary medicine · 2016Pooled it
- Pooled it
- The zoonotic potential of Mycobacterium avium ssp. paratuberculosis: a systematic review and meta-analyses of the evidence.Epidemiology and infection · 2015Pooled it
- Activation of mucosal-associated invariant T cells in the lungs of sarcoidosis patients.Scientific reports · 2019Trial
- Endogenous Hypersensitivity Infection: A Unifying Framework forMicroorganisms · 2026Review
- Review
- Diagnosis and treatment of sarcoidosis based on immunological etiology and mechanisms.Frontiers in medicine · 2026Review
- The Role ofInternational journal of molecular sciences · 2025Review
- Sarcoidosis: molecular mechanisms and therapeutic strategies.Molecular biomedicine · 2025Review
- Pathological diversity of pulmonary sarcoidosis.Frontiers in medicine · 2025Review
- Latent microbial reactivation and immune dysregulation in sarcoidosis: bridging pathogenesis and precision therapeutics.Frontiers in medicine · 2025Review
- Intracellular infection of Cutibacterium acnes in macrophages of extensive peri-implantitis lesions: A clinical case series.Clinical implant dentistry and related research · 2024Article
- Lung microbiome: new insights into the pathogenesis of respiratory diseases.Signal transduction and targeted therapy · 2024Review
- AWMF mold guideline "Medical clinical diagnostics for indoor mold exposure" - Update 2023 AWMF Register No. 161/001.Allergologie select · 2024Article
- Lung fibrosis in sarcoidosis. Is there a place for antifibrotics?Frontiers in pharmacology · 2024Review
- Article
- Bilateral Dacryoadenitis As the First Presentation in an Undiagnosed Sarcoidosis Patient.Cureus · 2023Article
- Interleukin-17A plays a key role in pulmonary fibrosis followingExperimental biology and medicine (Maywood, N.J.) · 2023Article
- Efzofitimod: a novel anti-inflammatory agent for sarcoidosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2023Article
- Potential Association ofMicroorganisms · 2023Review
73 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 10 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cause(s) of sarcoidosis is unknown. Mycobacterium spp. are suspected in Europe and Propionibacterium spp. are suspected in Japan. The present international collaboration evaluated the possible etiological links between sarcoidosis and the suspected bacterial species. Formalin-fixed and paraffin-embedded sections of biopsy samples of lymph nodes, one from each of 108 patients with sarcoidosis and 65 patients with tuberculosis, together with 86 control samples, were collected from two institutes in Japan and three institutes in Italy, Germany, and England. Genomes of Propionibacterium acnes, Propionibacterium granulosum, Mycobacterium tuberculosis, Mycobacterium avium subsp. paratuberculosis, and Escherichia coli (as the control) were counted by quantitative real-time PCR. Either P. acnes or P. granulosum was found in all but two of the sarcoid samples. M. avium subsp. paratuberculosis was found in no sarcoid sample. M. tuberculosis was found in 0 to 9% of the sarcoid samples but in 65 to 100% of the tuberculosis samples. In sarcoid lymph nodes, the total numbers of genomes of P. acnes or P. granulosum were far more than those of M. tuberculosis. P. acnes or P. granulosum was found in 0 to 60% of the tuberculosis and control samples, but the total numbers of genomes of P. acnes or P. granulosum in such samples were less than those in sarcoid samples. Propionibacterium spp. are more likely than Mycobacteria spp. to be involved in the etiology of sarcoidosis, not only in Japanese but also in European patients with sarcoidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.